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We have recently encountered with a 9 month old boy, the
second in birth order of non-consanguineous parents who pre-
sented to the genetics clinic by coma. He was born by cesarean
section due to decreased fetal kicks with a birth weight of
2.8 kg. The main complaint of the parents before his presenta-
tion was the severe failure to thrive documented by his weight
of five kg at presentation. He had global developmental delay
as he was unable to support his head till the age of 6 months
and was unable to sit till his presentation. He was able to reach
objects at the age of 6 months but was not able to transfer
objects from one hand to the other. He was able to recognize
his parents at the age of 6 months.
At the age of 8 months, he had an event of pneumonia
and a week later he developed convulsions that progressed
rapidly to coma and was diagnosed as encephalitis. He
received anticonvulsants, antibiotics, antiviral treatments
with no response regarding coma recovery although his chest
infection improved and the convulsions were controlled.
Brain magnetic resonance Imaging (MRI) brain revealed
bilateral deep cerebral white matter hypomyelination. Both
metachromatic leukodystrophy and Krabbe disease were
excluded by enzyme assay. The patient was then referred
to exclude metabolic encephalopathy. Extended metabolic
screen was done by tandem mass spectrometry and showed
increased phenylalanine level to 748 lmol/l (normal 0–180)
and increased glycine level of 657 (normal 0–341). Urinary
organic acids showed increased phenyl lactic, phenyl acetic
and phenyl pyruvic acid. Urine neopterin and biopterin anal-
ysis showed low biopterin (0.14 mmol/mol creatinine, normal
value = 0.70–5.300) and elevated neopterin (60.66 mmol/mol
creatinine, N= 1.20–14.50) indicative for tetrahydro-
biopterin (BH4) biosynthesis deficiency, specifically 6-pyru-
voyltetrahydropterin synthase (PTPS) deficiency which was
confirmed by molecular testing which revealed homozygous
for c.200C>T, p.(Thr67Met) of the 6-pyruvoyltetra-
hydropterin synthase (PTS) gene. Unfortunately the
patient died before testing result of the urine neopterin
was finished.Discussion
BH4 deficiency is considered a very rare disease with an
estimated prevalence of one in million live births in
western countries and expected to be higher in some Mediter-
ranean countries [1]. Actually, it is a group of diseases with
several enzymes involved including GTP cyclohydrolase 1,
sepiapterin reductase, 6-pyruvoyl-tetrahydropterin synthase,
pterin-4-alpha reductase and dihysropteridine reductase
[2]. The clinical presentation is more severe than phenylalanine
hydroxylase deficiency because it involves CNS neurotrans-
mitters biosynthesis, most commonly progressive mental
retardation that is unresponsive to treatment with low pheny-
lalanine diet, abnormal movement, impaired tone and convul-
sions [3].
As far as our knowledge, coma was not reported before in
patients with BH4 deficiency. The diagnosis of this patient was
a challenge for the treating physician, not only due to the atyp-
ical presentation but also because of the MRI brain finding of
severe hypomyelination. The presence of white matter affec-
tion in patients with untreated PKU should not misdirect the
physician and restrict his diagnosis only to lysosomal storage
diseases. The high phenylalanine level competes with other
large neutral amino acids (LNAA) for a carrier responsible
for their uptake into the CNS. The low level of LNAA
may inhibit the development of myelin. These abnormalities
tend to be more frequent and more severe in older patients
who are off treatment and those with higher phenylalanine
levels [4].
Why this patient was not diagnosed before his presentation
will be the second lesson to the young physicians. The patient
had two important signs that should have directed the physi-
cian to exclude inborn errors of metabolism: global develop-
mental delay and failure to thrive. Although newborn
screening for phenylketonuria (PKU) is now available in
Egypt, it was not established except few months ago and still
do not cover all governorates and so the diagnosis of PKU
should be excluded in every child with global developmental
delay.
Whether the earlier diagnosis would have saved this patient
or not will still be an argument. Only few studies have reported
the long-term outcome of patients with PTPS deficiency.
242 EditorialThe overall developmental delay after treatment was 38%
(35% in those with early diagnosis and 44% of those with late
diagnosis). The study was done on only 26 patients [5]. In
another study the outcome of the severe form of PTPS defi-
ciency was influenced by the precocity of the treatment [6].
The third lesson is that taking samples in critically ill
patient is of high priority for proper genetic counseling to
the family. Without this step, this patient would have never
been diagnosed and the family would have been counseled that
the child had a severe form of infection that passed to his CNS
and have led to his death.
To conclude, BH4 deficiency can present an encephalopa-
thy like picture. Reaching an accurate diagnosis is crucial
not only because of the importance of initiation of early treat-
ment but also for proper genetic counseling and family
planning.Acknowledgments
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